Lantern Pharma Inc. Operating Income Loss

• Lantern Pharma Inc. showed an increase of +19.1% in Operating Income Loss from 2024 to 2025.
• This data is from Lantern Pharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), Lantern Pharma Inc.'s Operating Income Loss has declined by 42.8%.
• Historical annual values: Fiscal year 2025: -$17.98 million | Fiscal year 2024: -$22.22 million | Fiscal year 2023: -$17.88 million | Fiscal year 2022: -$14.43 million | Fiscal year 2021: -$12.59 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026